Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | CPT2 | P23786 | 1/20 | 0.45 |
| ▸ | HMGCR | P04035 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12466056 | 1.00 | TDP1 (0.45) | TDP1KDM4EFFAR1CPT2HMGCR | |
| SCHEMBL12466058 | 1.00 | TDP1 (0.45) | TDP1KDM4EFFAR1CPT2HMGCR | |
| SCHEMBL2467205 | 0.86 | TSHR (0.46) | TDP1KDM4EFFAR1CPT2TSHR | |
| SCHEMBL2467206 | 0.86 | TSHR (0.46) | TDP1KDM4EFFAR1CPT2TSHR | |
| SCHEMBL24859727 | 0.80 | CHRNB2 (0.42) | TDP1KDM4EFFAR1CPT2HMGCR | |
| SCHEMBL7278355 | 0.80 | HCAR2 (0.38) | TDP1TSHRGABRR1GABRR2BLM | |
| SCHEMBL11747350 | 0.80 | TSHR (0.41) | TDP1TSHRGABRR1GABRR2BLM | |
| SCHEMBL6243367 | 0.80 | CPT2 (0.46) | TDP1KDM4EFFAR1CPT2HMGCR | |
| SCHEMBL22500775 | 0.78 | FFAR1 (0.45) | TDP1KDM4EFFAR1CPT2HMGCR | |
| SCHEMBL22500777 | 0.78 | FFAR1 (0.45) | TDP1KDM4EFFAR1CPT2HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668190-B1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-08-17 | — | — | EP | disclosed |
| US-9309253-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-12 | — | — | US | disclosed |
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-05-21 | — | — | US | disclosed |
| US-8975267-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-10 | — | — | US | disclosed |
| EP-2668190-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-12-04 | — | — | EP | disclosed |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-07 | — | — | US | disclosed |
| WO-2012101032-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K6 | TDP1 861/4885KDM4E 1178/4885FFAR1 4290/4885 |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | TDP1 872/4885KDM4E 1386/4885FFAR1 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.